Irigaray between God and the Indians : sexuate difference, decoloniality, and the politics of ontology

In this essay, I situate Irigaray’s philosophy of sexuate difference between the Heideggerian response to the collapse of the project of Western modernity (‘only a god can save us’) and that of decolonial theorist Oscar Guardiola-Riviera (‘only Indians can save our modern soul’). First, I return to Heidegger’s theorisation of ‘planetary technicity’ as the ontology of modernity, arguing, with Heidegger, that in order to respond to this problem we must return to the question of Being. From here, I link Heidegger’s theory of technicity with the work of decolonial theory on the ‘coloniality of Being’, suggesting that one reason for Heidegger’s pessimism is that he did not think technicity from beyond a Eurocentric perspective. The recent ‘ontological turn’ in decolonial anthropology that seeks to study Indigenous thought as ontology, however, shows that there are resources for thinking beyond the onto-logic of technicity. Yet, here, I return to Irigaray’s critique of Heidegger for his forgetting of sexuate difference in his analysis of technology to say that a move to a decolonial ontology beyond planetary technicity can only take place if we go through an ontology of sexual difference: because, as Irigaray shows, the onto-logic of technicity that underwrites coloniality and modernity begins in an ontological annihilation of life, sexuate difference, and the maternal debt, the only way to recover this is by thinking the question of sexuate difference. Finally, I conclude by examining the case of the Kogi peoples of Colombia who have warned Westerners that the destruction of the planet can only be stopped if we learn to recompense our common Mother. This case, I suggest, shows how and why the turn to non-Western ontologies as a way out of the death project of modern technicity must reckon with the work of Irigaray

Sexual difference in/and the queer beyond of ethics

In her recent book, Are the Lips a Grave? A Queer Feminist on the Ethics of Sex, Lynne Huffer offers a daring call for a reconsideration of the rifts between feminist and queer theory in order to develop a "queer feminist ethics of eros" (Huffer 2013, 44). Arguing that sexual ethics lies at the fractured nexus between feminist and queer theory, Huffer seeks both to restore "a claim to an ethical queer feminism" and to transfigure ethics as "erotic living" (22). This project is clearly staged in the book's titular chapter, which provocatively brings together Michel Foucault's and Luce Irigaray's respective reformulations of sexual ethics with the so-called antisocial queer theory of Leo Bersani and Janet Halley. To my mind, one of the most invaluable contributions of Huffer's book is her queer reclamation of Irigaray's philosophy of sexual difference—a philosophy that many feminist and queer theorists alike have dismissed as irredeemably essentialist, conservative, heteronormative, and even homophobic, transphobic, and racist.1 For Huffer, however, "Irigaray's … absence from queer theory is evidence of a forgetting of her radical feminist practice as an always already queer method" (2013, 42). Taking off from Huffer's queer feminist rereading of Irigaray, I want to further queer ethics by exploring the relationship between ethics and sexual difference as it has been thought in European philosophy. First, I offer a critique of the conflation of queerness and "negativity" in antisocial queer theory and the abdication of ethical responsibility it ultimately entails. Following both Irigaray and Jacques Derrida, I then argue that sexual difference is wholly other (tout autre) to "the ethical" as it has been thought within phallogocentrism and, thus, I contend that justice demands a fidelity to this radical otherness of sexual difference. Queerness, I suggest, names precisely this "beyond" of the ethical—that is, sexual difference "itself"—and, thus, ironically, both queer and feminist theory must struggle for the heteros of sexual difference, beyond any distinction between she/he, hetero-/homosexual, friendship/love, or sex/eros

What does it mean to be living?

Our Western culture more and more moves away from life. It is so much so that speaking about nature is generally understood as alluding to some or other concept that would be more or less adequate, but not as referring to or questioning about life. This situation is all the stranger since we are facing a real danger regarding the survival of the earth and of all the living beings that populate it. It is as if all the discourses we hear about this problem could remain abstract considerations and academic or scientific evaluations and discussions without practical concern about our own life and our living environment. This probably results from the status of our discourse in general and its current relation to the real. There is no doubt that questions are little by little arising about the present situation of the world, and also that some of the recent philosophers have begun to inquire about the truth and their way of approaching it (as is the case, for example, with Nietzsche, Heidegger, and Merleau-Ponty). But it seems that, although they speak about the necessity of overcoming our past metaphysics, they succeed in doing that with difficulty. Could it be possible that the undertaking would be easier for a woman, because she did not actively contribute to the construction of our past metaphysics, and her identity and subjectivity have remained more in harmony with nature—which she is, furthermore, presumed to represent for the patriarchal tradition? Anyway, it seems that Luce Irigaray—in particular her last two books, Through Vegetal Being (coauthored with Michael Marder, 2016) and To Be Born (2017)—offers elements that correspond to what is at stake in our epoch, both at an empirical and a theoretical level. Hence this conversation about her approach to and treatment of issues crucial today for our life, our world, and all living beings

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada

Background It is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs. Methods Resource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer's perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study. Results The average per-person cost for screening individuals with LDCT was USD453 (95% confidence interval [CI], USD400–USD505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was USD33,344 (95% CI, USD31,553–USD34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, (USD47,792; 95% CI, USD43,254–USD52,200; p = 0.061). Conclusion In the Pan-Canadian study, the average cost to screen individuals with a high risk for developing lung cancer using LDCT and the average initial cost of curative intent treatment were lower than the average per-person cost of treating advanced stage lung cancer which infrequently results in a cure

Vitamin A and Retinoid Derivatives for Lung Cancer: A Systematic Review and Meta Analysis

Despite reported antiproliferative activity of vitamin A and its common use for cancer, there is no comprehensive synthesis of its safety and efficacy in lung cancers. To address this issue we conducted a systematic review of the safety and efficacy of vitamin A for the treatment and prevention of lung cancers.Two independent reviewers searched six electronic databases from inception to July 2009 for clinical, observational, and preclinical evidence pertaining to the safety and efficacy of vitamin A and related retinoids for lung cancers. 248 studies were included for full review and analysis. Five RCTs assessed treatment of lung cancers, three assessed primary prevention, and three looked at secondary prevention of lung cancers. Five surrogate studies, 26 phase I/II, 32 observational, and 67 preclinical studies were also included. 107 studies were included for interactions between vitamin A and chemo- or radiation-therapy. Although some studies demonstrated benefits, there was insufficient evidence overall to support the use of vitamin A or related retinoids for the treatment or prevention of lung cancers. Retinyl palmitate combined with beta carotene increased risk of lung cancer in smokers in the large CARET trial. Pooling of three studies pertaining to treatment and three studies on secondary prevention revealed no significant effects on response rate, second primary tumor, recurrence, 5-year survival, and mortality. There was a small improvement in event free survival associated with vitamin A compared to controls, RR 1.24 (95% CI 1.13-1.35). The synthetic rexinoid bexarotene increased survival significantly among a subset of patients in two RCTs (p<0.014, <0.087).There is a lack of evidence to support the use of naturally occurring retinoids for the treatment and prevention of lung cancers. The rexinoid bexarotene may hold promise for use among a subset of patients, and deserves further study

Selenium and Lung Cancer: A Systematic Review and Meta Analysis

Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies.Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum<106 ng/mL), but increase risk of lung cancers in those with higher selenium (≥ 121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61-1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70-3.24); and all-cause-death, OR 0.93 (95%CI 0.79-1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy.Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context

Agent-Based Modeling of Endotoxin-Induced Acute Inflammatory Response in Human Blood Leukocytes

Inflammation is a highly complex biological response evoked by many stimuli. A persistent challenge in modeling this dynamic process has been the (nonlinear) nature of the response that precludes the single-variable assumption. Systems-based approaches offer a promising possibility for understanding inflammation in its homeostatic context. In order to study the underlying complexity of the acute inflammatory response, an agent-based framework is developed that models the emerging host response as the outcome of orchestrated interactions associated with intricate signaling cascades and intercellular immune system interactions.An agent-based modeling (ABM) framework is proposed to study the nonlinear dynamics of acute human inflammation. The model is implemented using NetLogo software. Interacting agents involve either inflammation-specific molecules or cells essential for the propagation of the inflammatory reaction across the system. Spatial orientation of molecule interactions involved in signaling cascades coupled with the cellular heterogeneity are further taken into account. The proposed in silico model is evaluated through its ability to successfully reproduce a self-limited inflammatory response as well as a series of scenarios indicative of the nonlinear dynamics of the response. Such scenarios involve either a persistent (non)infectious response or innate immune tolerance and potentiation effects followed by perturbations in intracellular signaling molecules and cascades.The ABM framework developed in this study provides insight on the stochastic interactions of the mediators involved in the propagation of endotoxin signaling at the cellular response level. The simulation results are in accordance with our prior research effort associated with the development of deterministic human inflammation models that include transcriptional dynamics, signaling, and physiological components. The hypothetical scenarios explored in this study would potentially improve our understanding of how manipulating the behavior of the molecular species could manifest into emergent behavior of the overall system

The James Webb Space Telescope Mission

Twenty-six years ago a small committee report, building on earlier studies, expounded a compelling and poetic vision for the future of astronomy, calling for an infrared-optimized space telescope with an aperture of at least $4m$. With the support of their governments in the US, Europe, and Canada, 20,000 people realized that vision as the $6.5m$ James Webb Space Telescope. A generation of astronomers will celebrate their accomplishments for the life of the mission, potentially as long as 20 years, and beyond. This report and the scientific discoveries that follow are extended thank-you notes to the 20,000 team members. The telescope is working perfectly, with much better image quality than expected. In this and accompanying papers, we give a brief history, describe the observatory, outline its objectives and current observing program, and discuss the inventions and people who made it possible. We cite detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space Telescope Overview, 29 pages, 4 figure

BRAZIER et al. INTEGRATIVE ONCOLOGY Integrative practices of Canadian oncology

Objective Cancer patients are increasingly known to use complementary medicine (CAM) during conventional treatment, but data are limited on how Canadian oncology health professionals attempt to assist patients with their use of CAM in the context of conventional cancer care. As part of a larger qualitative study assessing the perceptions of Canadian oncology health professionals regarding integrated breast cancer care, we undertook an exploration of current integrative practices of oncology health professionals. Design Using an interpretive description research design and purposive sampling, we conducted a series of in-depth qualitative interviews with various oncology health professionals recruited from provincial cancer agencies, hospitals, integrative clinics, and private practice setting